PMID- 28739711
OWN - NLM
STAT- MEDLINE
DCOM- 20170817
LR  - 20181202
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.
PG  - 4229-4232
AB  - BACKGROUND/AIM: Adrenal insufficiency is one of the adverse events (AEs) 
      associated with anti-programmed death-1 (PD1) therapy. Delaying diagnoses can 
      lead to serious conditions. It is necessary to elucidate detailed clinical 
      features of these AEs. PATIENTS AND METHODS: Patients treated with anti-PD-1 
      monotherapy or in combination with anti-cytotoxic T cell lymphocyte-4 therapy at 
      our hospital from January 2013 to December 2016 were identified. The patients' 
      clinical characteristics and laboratory and radiologic findings were collected. 
      RESULTS: Adrenal insufficiency occurred in 3% of the patients. All patients were 
      male. At the onset of symptoms, eosinophilia (>500/mul) was observed in four 
      cases. Eosinophilia was observed more than a month before onset of symptoms in 
      three cases. Other pituitary hormones remained relatively stable. Radiological 
      evidence of pituitary inflammation was detected only in one case. CONCLUSION: 
      Most anti-PD1-related adrenal insufficiency cases involved an isolated ACTH 
      deficiency. Eosinophilia may be an early indicator before the onset of symptoms.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Ariyasu, Ryo
AU  - Ariyasu R
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Horiike, Atsushi
AU  - Horiike A
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Yoshizawa, Takahiro
AU  - Yoshizawa T
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Dotsu, Yosuke
AU  - Dotsu Y
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Koyama, Junji
AU  - Koyama J
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Saiki, Masafumi
AU  - Saiki M
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Sonoda, Tomoaki
AU  - Sonoda T
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Nishikawa, Shingo
AU  - Nishikawa S
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Kitazono, Satoru
AU  - Kitazono S
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Yanagitani, Noriko
AU  - Yanagitani N
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan.
FAU - Nishio, Makoto
AU  - Nishio M
AD  - Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for 
      Cancer Research, Tokyo, Japan mnishio@jfcr.or.jp.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adrenal Insufficiency/chemically induced/*pathology
MH  - Adrenocorticotropic Hormone/deficiency
MH  - Aged
MH  - Antibodies, Monoclonal/administration & dosage/adverse effects
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects
MH  - Carcinoma, Non-Small-Cell Lung/complications/*drug therapy/genetics/pathology
MH  - Drug-Related Side Effects and Adverse Reactions/*pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nivolumab
MH  - Programmed Cell Death 1 Receptor/antagonists & inhibitors/*genetics
MH  - T-Lymphocytes, Cytotoxic/drug effects/pathology
OTO - NOTNLM
OT  - Anti-PD-1
OT  - adrenal insufficiency
OT  - isolated ACTH deficiency
OT  - nivolumab
OT  - pembrolizumab
EDAT- 2017/07/26 06:00
MHDA- 2017/08/18 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/06/15 00:00 [received]
PHST- 2017/07/01 00:00 [revised]
PHST- 2017/07/03 00:00 [accepted]
PHST- 2017/07/26 06:00 [entrez]
PHST- 2017/07/26 06:00 [pubmed]
PHST- 2017/08/18 06:00 [medline]
AID - 37/8/4229 [pii]
AID - 10.21873/anticanres.11814 [doi]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4229-4232. doi: 10.21873/anticanres.11814.